Enrique Poradosu
Oprichter bij NUVECTIS PHARMA, INC.
Vermogen: 10 M $ op 30-04-2024
Profiel
Enrique Poradosu is the founder of Nuvectis Pharma, Inc. which is founded in 2020, where he currently holds the title of Executive VP, Chief Scientific & Business Officer.
He held the position of Vice President-Business & Scientific Strategy at Keryx Biopharmaceuticals, Inc. from 2003 to 2016 and Senior VP-Business & Scientific Strategy at Stemline Therapeutics, Inc. from 2016 to 2020.
Dr. Poradosu received his undergraduate and doctorate degrees from The Hebrew University of Jerusalem.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NUVECTIS PHARMA, INC.
8.47% | 10-05-2024 | 1 504 319 ( 8.47% ) | 10 M $ | 30-04-2024 |
Actieve functies van Enrique Poradosu
| Bedrijven | Functie | Begin |
|---|---|---|
| NUVECTIS PHARMA, INC. | Oprichter | 27-07-2020 |
Eerdere bekende functies van Enrique Poradosu
| Bedrijven | Functie | Einde |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01-12-2020 |
| KERYX BIOPHARMACEUTICALS | Hoofd Techniek/Wetenschap/O&O | 01-01-2016 |
Opleiding van Enrique Poradosu
| The Hebrew University of Jerusalem | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
| Nuvectis Pharma, Inc. | |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
